Polynovo Ltd (ASX: PNV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Polynovo Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$683.93 million
P/E Ratio
100.00
Dividend Yield
0.00%
Shares Outstanding
690.84 million
Earnings per share
0.011
Dividend per share
N/A
Year To Date Return
-14.63%
Earnings Yield
1.00%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Polynovo Ltd (ASX: PNV)
Latest News
Broker Notes
Buy, hold, sell: Dicker Data, Polynovo, Flight Centre shares
Broker Notes
4 ASX shares scoring upgrades in the final week of earnings season
Healthcare Shares
PolyNovo FY26 earnings: Revenue jumps, profit steady
Healthcare Shares
Down 35% for the year, is it time to buy this beaten-down ASX biotech?
ASX Share Market News
5 things to watch on the ASX 200 on Friday
Healthcare Shares
PolyNovo FY26 earnings: Record revenue and cash flow
ASX Share Market News
Here are the 10 most shorted ASX shares
ASX Share Market News
These are the 10 most shorted ASX shares
ASX Share Market News
These are the 10 most shorted ASX shares
ASX Share Market News
These are the 10 most shorted ASX shares
Broker Notes
8 ASX 200 shares with renewed buy ratings this week
Broker Notes
Morgans names two ASX shares to buy right now for returns of 20% to 50%
Frequently Asked Questions
-
The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX on 26 November 1998 and is headquartered in Melbourne.
-
No, the company does not historically pay dividends.
PNV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Polynovo Ltd
PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.
NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.
PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.
PNV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 10 Sep 2026 | $1.00 | $-0.05 | -4.76% | 1,152,627 | $1.04 | $1.05 | $0.99 |
| 09 Sep 2026 | $1.05 | $0.00 | 0.00% | 994,894 | $1.04 | $1.06 | $1.04 |
| 08 Sep 2026 | $1.06 | $0.01 | 0.96% | 1,929,130 | $1.04 | $1.08 | $1.03 |
| 07 Sep 2026 | $1.04 | $0.01 | 0.97% | 3,344,262 | $1.03 | $1.07 | $1.03 |
| 04 Sep 2026 | $1.03 | $0.01 | 0.98% | 1,206,616 | $1.01 | $1.06 | $1.01 |
| 03 Sep 2026 | $1.02 | $0.02 | 2.00% | 1,643,444 | $1.01 | $1.03 | $0.99 |
| 02 Sep 2026 | $1.00 | $0.00 | 0.00% | 1,538,028 | $1.02 | $1.03 | $0.98 |
| 01 Sep 2026 | $1.01 | $0.00 | 0.00% | 1,182,114 | $1.00 | $1.02 | $0.99 |
| 31 Aug 2026 | $1.01 | $-0.04 | -3.85% | 1,987,186 | $1.03 | $1.05 | $1.00 |
| 28 Aug 2026 | $1.04 | $0.01 | 0.97% | 1,859,398 | $1.02 | $1.09 | $1.01 |
| 27 Aug 2026 | $1.03 | $0.03 | 2.99% | 5,914,277 | $1.05 | $1.17 | $1.02 |
| 26 Aug 2026 | $1.01 | $-0.06 | -5.66% | 4,601,594 | $1.05 | $1.05 | $0.93 |
| 25 Aug 2026 | $1.06 | $0.02 | 1.91% | 1,352,584 | $1.07 | $1.07 | $1.03 |
| 24 Aug 2026 | $1.05 | $-0.03 | -2.80% | 1,175,962 | $1.07 | $1.08 | $1.04 |
| 21 Aug 2026 | $1.07 | $-0.04 | -3.60% | 1,904,071 | $1.09 | $1.10 | $1.06 |
| 20 Aug 2026 | $1.11 | $0.07 | 6.73% | 2,582,808 | $1.03 | $1.12 | $1.03 |
| 19 Aug 2026 | $1.04 | $-0.01 | -0.95% | 2,471,729 | $1.07 | $1.09 | $1.04 |
| 18 Aug 2026 | $1.06 | $0.04 | 3.96% | 4,219,167 | $1.00 | $1.12 | $1.00 |
| 17 Aug 2026 | $1.01 | $0.05 | 5.18% | 4,791,791 | $0.97 | $1.04 | $0.96 |
| 14 Aug 2026 | $0.97 | $0.02 | 2.12% | 2,073,105 | $0.94 | $0.97 | $0.93 |
| 13 Aug 2026 | $0.95 | $0.00 | 0.00% | 1,429,646 | $0.95 | $0.95 | $0.92 |
| 12 Aug 2026 | $0.95 | $-0.01 | -1.05% | 1,184,151 | $0.95 | $0.96 | $0.93 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Mar 2026 | Robert Douglas | Buy | 151,000 | $140,430 |
On-market trade. USD
|
| 25 Feb 2026 | Leon Hoare | Buy | 30,000 | $28,071 |
On-market trade.
|
| 24 Feb 2026 | Andrew Lumsden | Buy | 100,000 | $91,364 |
On-market trade. $0.9136 average price per share
|
| 19 Sep 2025 | David Williams | Buy | 55,000 | $87,997 |
On-market trade. As per announcement
|
| 17 Sep 2025 | Robyn Elliott | Buy | 20,000 | $32,000 |
On-market trade.
|
| 15 Sep 2025 | David Williams | Buy | 50,030 | $75,045 |
On-market trade.
|
| 12 Sep 2025 | David Williams | Buy | 61,335 | $85,975 |
On-market trade.
|
| 11 Sep 2025 | Leon Hoare | Buy | 20,000 | $27,830 |
On-market trade. As per announcement
|
| 11 Sep 2025 | David Williams | Buy | 31,000 | $42,933 |
On-market trade. As per announcement
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Robyn Elliott | Non-Executive Director | Oct 2019 |
Dr Elliott was Global Head, Strategic Portfolio Management at CSL Behring. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding. He is also member of Risk Committee.
|
| Mr Andrew Stuart Lumsden | Non-Executive Director | Jun 2021 |
Mr Lumsden is Chartered Accountant and finance executive with 25 years' experience locally and internationally. He is also a member of the Australian Institute of Company Directors. He previously served as Chief Executive Officer of Wellcom Worldwide Australasia. He is also Chair of Risk Committee.
|
| Mr Leon Hoare | Non-Executive DirectorNon-Executive Chairman | Jan 2016 |
Mr Hoare has expertise across multiple Life Sciences sectors. He served as Managing Director of Lohmann & Rauscher, Australia and New Zealand (ANZ). He was Managing Director of Smith & Nephew (S&N) ANZ. He is currently a Non-Executive Director of Medical Developments International Ltd.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | May 2020 |
Ms Emmanuel-Donnelly is an IP and business development professional with more than 30 years of local and international experience. She is currently Chair of Impedimed Ltd and on the Board of Medical Developments International Ltd.
|
| Dr Charmaine Hilary Gittleson | Non-Executive Director | Apr 2026 |
Dr Gittleson has experience across healthcare, life sciences and governance, with a background spanning clinical practice and research, medical leadership, regulatory strategy, product development and board oversight. She is the former Chief Medical Officer of CSL. She is currently Chair of Percheron Therapeutics Ltd, and a Non-Executive Director of Imugene Limited and George Medicines Ltd.
|
| Mr Robert Douglas | Non-Executive Director | Oct 2025 |
Mr Douglas has thirty-five years of experience in medical device technology, specialising in digital health. He is currently a member of the Board
of Directors for Globus Medical Inc. He is also member of Risk Committee |
| Mr Jan-Marcel Gielen | Company Secretary | Dec 2018 |
-
|
| Mr Swami Raote | Chief Executive Officer | Jul 2022 |
-
|
| Ms Amy Demediuk | General Counsel Company Secretary | Feb 2026 |
-
|
| Swami Raote | Chief Executive Officer |
-
|
|
| Bruce Peatey | Chief Executive Officer |
-
|
|
| Jan-Marcel Gielen | Chief Financial Officer |
-
|
|
| Jan-Marcel Gielen | Company Secretary |
-
|
|
| Amy Demediuk | General Counsel Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 58,676,167 | 8.49% |
| HSBC Custody Nominees (Australia) Limited | 53,477,032 | 7.74% |
| Citicorp Nominees Pty Limited | 41,830,253 | 6.05% |
| Moggs Creek Pty Ltd (Moggs Creek Super A/C) | 19,394,477 | 2.81% |
| BNP Paribas Noms Pty Ltd | 18,508,538 | 2.68% |
| BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) | 13,476,413 | 1.95% |
| BNP Paribas Nominees Pty Ltd (Hub24 Custodial Serv Ltd) | 12,521,540 | 1.81% |
| Lateral Innovations Pty Ltd | 10,924,103 | 1.58% |
| Jekl Super Pty Ltd (Kittel Fam SF A/C) | 8,355,000 | 1.21% |
| SCJ Pty Limited (Jermyn Family A/C) | 5,000,000 | 0.72% |
| Netwealth Investments Limited (Wrap Services A/C) | 4,954,215 | 0.72% |
| BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 3,740,506 | 0.54% |
| Dr George Bousounis Commonwealth | 3,664,694 | 0.53% |
| BNP Paribas Nominees Pty Ltd (Clearstream) | 3,621,566 | 0.52% |
| Mr Paul Gerard Brennan | 3,569,796 | 0.52% |
| Mr David Kenley | 3,520,000 | 0.51% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston (Kuranga Nursery Super A/C) | 3,149,149 | 0.46% |
| Mr David Kenley 1 | 3,139,855 | 0.45% |
| Dr Marcus James Dermot Wagstaff & Mrs Lara Kate Wagstaff | 3,072,166 | 0.44% |
| Mr Christopher Mark Dawborn & Ms Leanne Nelms (Haskali Super Fund AC A/C) | 2,900,000 | 0.42% |
